The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Is an adult patient with a confirmed diagnosis of T2DM
Has a body mass index (BMI) of ≥23 kg/m² to ≤39.9 kg/m²
Has a hemoglobin A1c (HbA1c) ≥6.5% to <10.5%
Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)
Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods